EnVivo Pharmaceuticals reported positive results of its randomized, placebo-controlled Phase 2b clinical trial of EVP-6124, an orally bioavailable and selective alpha-7 agonist, in patients with schizophrenia.
The data showed EVP-6124 had a clinically meaningful and statistically significant impact on patients’ overall cognition when taken in combination with second-generation antipsychotics and as measured by the full CogState overall cognitive index (OCI).
Results from this Phase 2b trial demonstrated that patients treated with EVP-6124 showed clinically meaningful and statistically significant effects in key secondary endpoints: improvement in clinical function and reduction of the negative symptoms of schizophrenia.
“EVP-6124 represents a novel, rational approach, supported by extensive basic research, to improve cognition in schizophrenia. This initial clinical trial is highly encouraging that this novel approach has the potential to address what many consider the greatest unmet pharmacologic need for schizophrenia,” says Herbert Y. Meltzer, MD, PhD, the Bixler/May/Johnson professor of psychiatry at Vanderbilt University.
“We are extremely excited by these data, which show a compelling and positive impact on a wide range of schizophrenia patients’ cognitive functions as measured by the CogState overall cognition index. Additionally, the ability of EVP-6124 to reduce schizophrenia’s debilitating negative symptoms further illustrates the drug’s promise and broad potential,” said Kees Been, president and chief executive officer, EnVivo Pharmaceuticals. “There are no currently approved therapies to treat cognitive and negative symptoms of the disease, so the opportunity to potentially address both cognition and negative symptoms is exciting and something that we will carefully evaluate as we move forward into later stages of development.”
Release Date: May 17, 2011
Filed Under: Drug Discovery